EVEREST MED (01952.HK): NMPA approves 100mg strength of XERAVA
- XERAVA is the world's first fluorocycline antibacterial, active against multidrug-resistant gram-negative and gram-positive bacteria, anaerobes and atypical pathogens.
- It is dosed by body weight at 1mg/kg every 12 hours; the 50mg strength was approved in China in 2023 for adult cIAI.
NewTimeSpace News: On 13 November 2026, Everest Medicines Limited (stock code: 01952) said China's NMPA approved a 100mg strength of XERAVA (eravacycline for injection, branded Yijia in Chinese). XERAVA is the world's first and only fully synthetic fluorocycline antibacterial as of November 2026, with a broad spectrum and good safety, and is recommended by Chinese and international guidelines for empirical treatment of complicated intra-abdominal infections (cIAI).
It is dosed by body weight at 1mg/kg every 12 hours; the new strength gives a more flexible option that cuts preparation steps and drug waste. The 50mg strength was approved in China in 2023 for adult cIAI, and XERAVA was cleared by the NMPA in March 2023 and launched in mainland China that July. The Jiashan base has obtained a production licence and localisation is under way, with process validation completed for the 50mg form.
- HK Stock Connect Daily Report: EVEREST MED Surges Over 18%, KINGBOARD Group Leads PCB, LEAPMOTOR Profit Soars 530% - 20260825
- HK Stock Connect Daily Report: Pharmaceutical Sector Explodes Across the Board, EVEREST MED Surges 41%! KUAISHOU-W Drops 11% After Results - 20260820
- EVEREST MED(01952.HK): 2026 Interim Report - Profit Attributable to Shareholders stood at loss of CNY 5.94 million, loss narrowed by 97.62% YoY
- EVEREST MED(01952.HK): Closing Completed for Exclusive Licensing Collaboration with Travere; Upfront Payment of USD112.5 Million
- EVEREST MED(01952.HK): Enters Commercialization Cooperation with Hainan Herui for Budesonide Enteric Capsules
